Capital Genomix

Capital Genomix is a small U.S.-based life science company focused on genomics, proteomics, and immunology technologies. Historically, the company developed and marketed proprietary platforms including GeneSystem320, a gene expression analysis system licensed from MD Anderson Cancer Center, and ImmunoMouse, an antibody-related technology associated with immunotherapy and diagnostic development. More recently, its website presents the business primarily as a supplier of research and diagnostic products, including antibodies, genomics and transcriptomics reagents, sequencing tools, FISH probes, microbial identification reagents, and related laboratory consumables. Publicly available information suggests the company remains active as a private company, but there is limited evidence of a current proprietary therapeutic pipeline or clinical-stage drug development program. For a biotech analyst, Capital Genomix appears best characterized as an early-stage/platform-oriented biotechnology company that evolved toward research products and laboratory services rather than a conventional clinical therapeutics developer.